[Evaluation of the effectiveness and tolerability of gliquidone in the treatment of diabetes mellitus type II]

Abstract

The effectiveness of treatment with gliquidone, a second generation sulphonylurea, was assessed for six months in 40 type II diabetic outpatients with poorly metabolic control (fasting plasma glucose greater than 180 mg/dl, HbA1c greater than 8%). After one-month therapy a good metabolic control was accomplished, which has been further increased over the following months (p less than 0.01 in comparison between glycemic profiles) with normalization of glycosylated hemoglobin values. No significant statistical changes have been reported in insulin and both fasting and after meal C-peptide levels. Results have been attained with low incidence in hypoglycemic reactions and an overall good tolerability of the compound.